;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AAV1-FS344: Phase I/IIa data

    Milo Biotechnology LLC, Cleveland, Ohio Product: AAV1-FS344 Business: Musculoskeletal Molecular target: Myostatin (GDF8) (MSTN) Description: Adeno-associated virus (AAV) vector used to deliver follistatin Indication: …

    Published on 10/27/2014
  • Afatinib: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Afatinib (Giotrif, Tomtovok) (BIBW 2992) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (HER1) (ErbB1); Epidermal growth factor …

    Published on 10/27/2014
  • Afatinib: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Afatinib (Giotrif, Tomtovok) (BIBW 2992) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (HER1) (ErbB1); Epidermal growth factor …

    Published on 10/27/2014
  • Binimetinib: Phase II final data

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Binimetinib (MEK162) (formerly ARRY-162) Business: Cancer Molecular target: MEK Description: Small …

    Published on 10/27/2014
  • Duvelisib: Phase IIa data

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Duvelisib (IPI-145) (formerly INK-1197) Business: …

    Published on 10/27/2014
  • Empagliflozin/linagliptin: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Empagliflozin/linagliptin Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter 2 (SGLT2); …

    Published on 10/27/2014
  • Fluticasone propionate/formoterol: Phase III data

    SkyePharma plc (LSE:SKP), London, U.K. Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Mundipharma International Ltd., Cambridge, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Fluticasone …

    Published on 10/27/2014
  • H7N9 avian influenza vaccine: Phase II data

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: H7N9 avian influenza vaccine Business: Infectious Molecular target: NA Description: Monovalent influenza A/H7N9 virus vaccine made with hemagglutinin (HA) antigen …

    Published on 10/27/2014
  • Lotemax loteprednol etabonate: Phase III data

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: Lotemax loteprednol etabonate Business: Ophthalmic Molecular target: Corticoid receptors Description: Topical steroid Indication: …

    Published on 10/27/2014
  • Mongersen: Phase II data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Nogra Pharma Ltd., Dublin, Ireland Product: Mongersen (GED-0301) Business: Autoimmune Molecular target: SMAD family member 7 (MADH7) (SMAD7) Description: Antisense …

    Published on 10/27/2014
  • Olodaterol/tiotropium: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Olodaterol/tiotropium Business: Pulmonary Molecular target: Muscarinic receptor; Adrenergic receptor beta 2 (ADRB2) Description: Once-daily fixed-dose combination …

    Published on 10/27/2014
  • RG-101: Phase I data

    Regulus Therapeutics Inc. (NASDAQ:RGLS), San Diego, Calif. Product: RG-101, Anti-miR-122 Business: Infectious Molecular target: MicroRNA-122 (miR-122) Description: GalNAc-conjugated antagonist targeting miR-122 …

    Published on 10/27/2014
  • RXI-109: Interim Phase IIa data

    RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Product: RXI-109 Business: Dermatology Molecular target: Connective tissue growth factor (CTGF) Description: Self-delivering rxRNA (sd-rxRNA) compound …

    Published on 10/27/2014
  • Secukinumab: Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Human IgG1 mAb targeting IL-17A Indication: Treat …

    Published on 10/27/2014
  • Secukinumab: Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Human IgG1 mAb targeting IL-17A Indication: Treat …

    Published on 10/27/2014
  • Sepranolone: Phase II final data

    Umecrine Co. Group, Umea, Sweden Product: Sepranolone (UC1010) Business: Endocrine/Metabolic Molecular target: GABA A receptor Description: GABA A modulating steroid antagonist Indication: Treat premenstrual dysphoric …

    Published on 10/27/2014
  • SER100: Preliminary Phase IIa data

    Serodus ASA (OSE:SER), Oslo, Norway Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: SER100 (formerly ZP120) Business: Cardiovascular Molecular target: Opiate receptor-like 1 (OPRL1) Description: Opiate …

    Published on 10/27/2014
  • UX023: Extension study data

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: UX023, KRN23 Business: Musculoskeletal Molecular target: Fibroblast growth factor 23 (FGF23) …

    Published on 10/27/2014
  • ACT 1: Phase II data

    FirstString Research Inc., Mount Pleasant, S.C. Product: ACT 1 (Granexin gel) Business: Dermatology Molecular target: Gap junction protein alpha 1, 43kDa (GJA1) (CX43) (connexin-43) Description: Bioengineered peptide …

    Published on 10/20/2014
  • Ameluz: Preliminary Phase III data

    Biofrontera AG (Xetra:B8F), Leverkusen, Germany Product: Ameluz (BF-200 ALA) Business: Dermatology Molecular target: Not available Description: Photodynamic therapy (PDT) consisting of nanoemulsion BF-200 with 5-…

    Published on 10/20/2014
  • Autologous T cell therapy against CD19: Phase I data

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Product: Autologous T cell therapy against CD19 (KTE-C19) Business: Cancer Molecular target: CD19 Description: Autologous T cells genetically modified to express a …

    Published on 10/20/2014
  • CTL019: Additional Phase I/IIa data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland University of Pennsylvania, Philadelphia, Pa. Product: CTL019 (formerly CART-19) Business: Cancer Molecular target: CD19 Description: Autologous T cells loaded with a…

    Published on 10/20/2014
  • CyclASol: Phase I data

    Novaliq GmbH, Heidelberg, Germany Product: CyclASol Business: Ophthalmic Molecular target: NA Description: 0.05% clear cyclosporin solution developed using Novaliq's EyeSol semi-fluorinated alkane (SFA) drug delivery …

    Published on 10/20/2014
  • ELI-200: Clinical trial data

    Elite Pharmaceuticals Inc. (OTCBB:ELTP), Northvale, N.J. Product: ELI-200 Business: Neurology Molecular target: NA Description: Abuse deterrent-formulation of an undisclosed opioid agonist and naltrexone Indication: …

    Published on 10/20/2014
  • Enhanced TCR therapy targeting NY-ESO-1: Interim Phase I data

    Adaptimmune Ltd., Abingdon, U.K. Product: Enhanced TCR therapy targeting NY-ESO-1 Business: Cancer Molecular target: Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1) Description: T cells genetically modified to express T …

    Published on 10/20/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993